甲磺酸阿帕替尼联合依托泊苷治疗铂耐药复发卵巢癌的效果

Efficacy of Apatinib Mesylate combined with Etoposide in the treatment of Platinum-resistant recurrent ovarian cancer

目的分析甲磺酸阿帕替尼联合依托泊苷治疗铂耐药复发卵巢癌的优势。方法选取2020年6月至2022年1月十堰市太和医院妇科收治的80例铂耐药复发卵巢癌患者作为研究对象,按照入院时间先后的顺序,将其分为观察组(40例)和对照组(40例)。对照组采用单一口服依托泊苷治疗,观察组采用甲磺酸阿帕替尼片以及依托泊苷治疗,比较两组患者治疗效果、毒副反应以及治疗前后糖类抗原125(CA125)指标。结果观察组患者治疗后的总缓解率高于对照组,差异有统计学意义(P<0.05);观察组患者治疗后的CA125低于对照组,差异有统计学意义(P<0.05);观察组患者治疗后生活质量分值高于对照组,差异有统计学意义(P<0.05);观察组治疗后搏动指数(PI)、阻力指数(RI)高于对照组,差异有统计学意义(P<0.05);观察组治疗后收缩峰值流速(PSV)低于对照组,差异有统计学意义(P<0.05);两组患者并发症总发生率比较,差异无统计学意义(P>0.05)。结论甲磺酸阿帕替尼联合依托泊苷为铂耐药复发性卵巢患者提供了一种新型、安全的治疗方案,可以延长患者生存时间。

Objective To analyze the advantages of Apatinib Mesylate combined with Etoposide in the treatment of Platinum-resistant recurrent ovarian cancer.Methods A total of 80 Platinum-resistant recurrent ovarian cancer patients admitted to the Department of Gynecology of Taihe Hospital from June 2020 to January 2022 were selected as research subjects.They were divided into observation group(40 cases)and control group(40 cases)based on the order of admission time.The control group was treated with single oral Etoposide,while the observation group was treated with Apatinib Mesylate Tablets and Etoposide.The treatment efficacy,toxicity,and carbohydrate antigen 125(CA125)before and after treatment were compared between the two groups.Results The total remission rate of the observation group after treatment was higher than that of the control group,with statistically significant difference(P<0.05).The CA125 of the observation group after treatment was lower than that of the control group,with statistically significant difference(P<0.05).The quality of life score of the observation group after treatment was higher than that of the control group,with statistically significant difference(P<0.05).After treatment,the pulsatility index(PI)and resistance index(RI)of the observation group were higher than those of the control group,with statistically significant differences(P<0.05).The peak systolic velocity(PSV)of the observation group after treatment was lower than that of the control group,with statistically significant difference(P<0.05).There was no statistically significant difference in the total incidence of complications between the two groups of patients(P>0.05).Conclusion Apatinib Mesylate combined with Etoposide provides a novel and safe treatment option for Platinum-resistant recurrent ovarian cancer patients,which can prolong their survival time.